Sarcoma  >>  Lartruvo (olaratumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lartruvo (olaratumab) / Eli Lilly
KEYNOTE-505, NCT03126591: A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
1a/1b
38
Europe, US
Olaratumab, LY3012207, Pembrolizumab, MK3475
Eli Lilly and Company, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma
05/21
02/23
NCT02783599: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Completed
1b
51
Europe, US
Olaratumab, LY3012207, Doxorubicin, External Beam Radiotherapy
Eli Lilly and Company
Soft Tissue Sarcoma
07/18
07/18
NCT03283696: A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
1b
24
Europe, US
Olaratumab, LY3012207, Doxorubicin, Ifosfamide, Mesna
Eli Lilly and Company
Soft Tissue Sarcoma
04/19
08/19
ANNOUNCE 2, NCT02659020 / 2015-001316-34: A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Completed
1b
310
Europe, US, RoW
Olaratumab, LY3012207, IMC-3G3, Gemcitabine, LY188011, Gemzar, Docetaxel, Placebo
Eli Lilly and Company
Soft Tissue Sarcoma
07/20
04/21
NCT02326025: A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

Completed
1
49
US
Olaratumab, LY3012207, IMC-3G3, Doxorubicin
Eli Lilly and Company
Sarcoma, Soft Tissue
05/15
11/18
NCT02377752: A Study of Olaratumab in Japanese Participants With Advanced Cancer

Completed
1
25
Japan
Olaratumab, LY3012207, IMC-3G3, Doxorubicin
Eli Lilly and Company
Neoplasm
08/18
01/20
OLATRASTS, NCT03985722: Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients

Active, not recruiting
1
28
Europe
Olaratumab and Trabectedin, Lartruvo and Yondelis
Grupo Espanol de Investigacion en Sarcomas
Sarcoma, Soft Tissue
02/21
05/24
NCT03437070: Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

Withdrawn
1
0
NA
Trabectedin, Yondelis, Doxorubicin, Doxorubicin Hydrochloride, Olaratumab, Lartruvo
University of Miami, Janssen Scientific Affairs, LLC
Leiomyosarcoma
06/21
06/23
NCT03056599: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Completed
1
23
US
Multiple drug microinjection, Doxorubicin, Docetaxel, Gemcitabine, Interferon gamma, Pembrolizumab, Ipilimumab, Interferon alfa-2B, Bortezomib, Aldesleukin, Trabectedin, Eribulin, Olaratumab, Atezolizumab, Durvalumab, Avelumab, Nivolumab, Larotrectinib, Entrectinib, Avapritinib, Saline, CIVO device
Presage Biosciences, Fred Hutchinson Cancer Center, University of Washington, Northwell Health, Oregon Health and Science University
Soft Tissue Sarcoma Adult
07/21
09/21
ZOLAR, NCT06537596: 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma

Not yet recruiting
1
50
RoW
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Telix Pharmaceuticals (Innovations) Pty Ltd
Soft Tissue Sarcoma
12/25
06/26

Download Options